Update on Guillain‐Barré syndrome

@article{Rinaldi2013UpdateOG,
  title={Update on Guillain‐Barr{\'e} syndrome},
  author={Simon Rinaldi},
  journal={Journal of the Peripheral Nervous System},
  year={2013},
  volume={18}
}
  • S. Rinaldi
  • Published 1 June 2013
  • Medicine
  • Journal of the Peripheral Nervous System
Understanding of Guillain‐Barré syndrome (GBS) has progressed substantially since the seminal 1916 report by Guillain et al. Although Guillain, Barré, and Strohl summarised the syndrome based on observations of two French infantrymen, 2012 saw the beginning of an ambitious collaborative study designed to collect detailed data from at least 1,000 patients worldwide (IGOS, www.gbsstudies.org/about‐igos). Progress has been made in many areas even since GBS was last reviewed in this journal in 2009… 
Immunotherapy of Guillain-Barré syndrome
TLDR
Good circumstantial evidence exists for a pathogenic role for molecular mimicry in GBS pathogenesis, especially with its axonal forms, providing insights that could guide future immunotherapy, and the potential of leukocyte trafficking inhibitors as novel disease-specific immunotherapeutic drugs is highlighted.
Guillain-Barré syndrome associated with Mycobacterium bovis lymphadenitis
TLDR
A literature review revealing that the association between tuberculosis and Guillain-Barré syndrome is very rare (only seven cases previously reported) but is not coincidental is performed, and Physicians should be aware that tuberculosis can be a cause of GBS.
Guillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosis
TLDR
Novel prognostic models can accurately predict outcome and the need for artificial ventilation, which could aid the selection of patients with a poor prognosis for more-individualized care.
CSF Findings in Guillain-Barré Syndrome: Demyelinating and Axonal Acute Inflammatory Polyneuropathies
TLDR
Although most of these studies indicate alteration of the CSF and support the immunopathogenesis of GBS, albuminocytological dissociation described 100 years ago remains the only consistent CSF biomarker supporting the diagnosis of G BS after the second week of disease onset.
Novel Immunological and Therapeutic Insights in Guillain-Barré Syndrome and CIDP
  • L. Querol, C. Lleixà
  • Medicine, Biology
    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
  • 2021
TLDR
A topical review describes immunological progress that may help guide therapeutic strategies in the future in inflammatory neuropathies and Guillain-Barré syndrome, to optimize disease outcomes in CIDP and GBS.
UNDERSTANDING THE PATIENT’S RECALLED EXPERIENCE OF AN ACUTE EPISODE OF GUILLAIN-BARRE’ SYNDROME: A QUALITATIVE DESCRIPTIVE STUDY
TLDR
Five major themes were identified: physical manifestations of GBS, attitudes and emotions, knowledge and awareness, the value of peer contact, and care concepts, which suggest that healthcare team members, including nurses, do not have an understanding of Guillain-Barre’ syndrome.
Dissecting the Role of Anti-ganglioside Antibodies in Guillain-Barré Syndrome: an Animal Model Approach
TLDR
Development of anti-ganglioside antagonists can serve as targeted therapy for the treatment of GBS and will open a new approach of drug development with maximum efficacy and specificity.
The pathogenic relevance of αM-integrin in Guillain–Barré syndrome
The molecular determinants and mechanisms involved in leukocyte trafficking across the blood–nerve barrier (BNB) in the acute inflammatory demyelinating polyradiculoneuropathy (AIDP) variant of
...
1
2
3
...

References

SHOWING 1-10 OF 124 REFERENCES
Guillain‐Barré syndrome: background incidence rates in The Netherlands
TLDR
Age‐specific rates should be used to monitor GBS observed versus expected rates after introduction of large‐scale vaccination programmes, as vaccinations are often targeted at specific age groups.
Outcome and its predictors in Guillain–Barré syndrome
TLDR
Analysis of prognostic predictors consistently demonstrates the negative impact of higher age, preceding diarrhoea, greater disability/weaker muscles at admission, short interval between symptom-onset and admission, mechanical ventilation and absent/low amplitude compound muscle action potentials.
[Guillain-Barré syndrome].
TLDR
High-dose of intravenous immunoglobulin (0.4 g/kg daily for 5 days) and PE are equally effective in intermediate and severe forms and the choice between the two treatments depends on their respective contra-indications and local availability.
Guillain-Barré syndrome following primary cytomegalovirus infection: a prospective cohort study.
  • D. Orlikowski, R. Porcher, E. Gault
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2011
TLDR
This study provides new insights about the epidemiology ofCMV-GBS and shows that the risk of developing GBS is similar following primary CMV infection or C. jejuni infection, and suggests a direct or indirect involvement of viral replication in the neuropathological processes of CMV- GBS.
Guillain-Barré syndrome after exogenous gangliosides in Italy.
TLDR
More cases of the Guillain-Barre syndrome are reported and it is suggested that gangliosides may induce an immune response when made into a complex with serum or tissue proteins.
Preceding infections, immune factors, and outcome in Guillain–Barré syndrome
TLDR
Subtypes of GBS defined by preceding infections were only approximately associated with different patterns of clinical, neurophysiologic, and immunologic features, implying interaction with additional host factors.
Guillain-Barré syndrome
Electrophysiological classification of guillain‐barré syndrome: Clinical associations and outcome
TLDR
Patients with pure motor GBS, enrolled in a trial comparing plasma exchange, intravenous immunoglobulin, and both treatments, were more likely than other GBS patients to have IgG antiganglioside GM1 antibodies and to have had preceding diarrhea but had a similar outcome.
Incidence of Guillain-Barré syndrome following infection with Campylobacter jejuni.
TLDR
The incidence of Guillain-Barré syndrome (GBS) is measured in a large cohort of persons with laboratory-confirmed C. jejuni infection and the risk of developing GBS during the 2 months following a symptomatic episode of C.Jejuni gastroenteritis is approximately 100 times higher than the risk in the general population.
Lack of antibody response to Guillain–Barré syndrome-related gangliosides in mice and men after novel flu vaccination
TLDR
An assessment of the pandemic 2009 A (H1N1) and H5N1 vaccines' ability to induce antiganglioside antibodies in mice and humans is reported, providing information as to the possible risk of developing AMAN following these vaccinations.
...
1
2
3
4
5
...